Snap-8

Snap-8 (acetyl octapeptide-3; INCI: Acetyl Glutamyl Heptapeptide-3; sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2; CAS 868844-74-0) is a synthetic octapeptide developed by Lipotec SA (Barcelona, Spain; now Lubrizol) as an extended analog of Argireline (acetyl hexapeptide-3/8), with two additional residues (Ala-Asp) appended to the C-terminus.

The compound mimics the N-terminal domain of SNAP-25 (synaptosomal-associated protein, 25 kDa), a core component of the neuronal SNARE complex. The SNARE machinery (soluble N-ethylmaleimide-sensitive factor activating protein receptor) drives synaptic vesicle docking and fusion with the presynaptic membrane, enabling calcium-triggered acetylcholine release at the neuromuscular junction. By presenting a SNAP-25-like sequence, Snap-8 competes with native SNAP-25 for binding within the SNARE assembly, attenuating neurotransmitter exocytosis.

The theoretical downstream effect is reduced amplitude and frequency of facial muscle micro-contractions, slowing the mechanical formation of dynamic expression lines. The inhibition is reversible and competitive, distinguishing it from botulinum toxin type A, which cleaves SNAP-25 irreversibly and produces complete neuromuscular blockade.

In manufacturer-sponsored chromaffin cell assays, Snap-8 at 1.5 mM yielded approximately 43% inhibition of glutamate release, modestly exceeding Argireline at equivalent concentrations.

The clinical evidence base for Snap-8 is limited and dominated by manufacturer-sponsored data. No independent, large-scale, double-blind, randomized controlled trial has been published specifically on acetyl octapeptide-3.

Lipotec (now Lubrizol) has reported a small split-face trial in which a cream containing 3% of the commercial 0.05% Snap-8 solution (approximately 0.0015% active peptide) was applied twice daily for 28 days. Wrinkle depth, assessed by silicone replica analysis, was reported to decrease by up to 38%, with a mean reduction of approximately 7.1% (Lipotec internal data, 2020, as cited in a 2020 Frontiers in Chemistry peer-reviewed review, PMC7662462). Manufacturer-linked commercial sources also cite a maximum reduction of up to 63% in a small participant subset, but this figure has not been independently validated in peer-reviewed literature and should be treated with caution.

An open-label 14-week clinical study published in the Journal of Drugs in Dermatology (2016) enrolled 29 women with mild to moderately photodamaged facial skin. The test serum contained acetyl octapeptide-3 alongside five other peptides (including acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, and palmitoyl tetrapeptide-7). Statistically significant improvements were reported in facial lines and periorbital wrinkles both at rest and at maximum smile. No adverse events occurred. Because the formula was multi-ingredient and lacked a control arm, the isolated contribution of Snap-8 cannot be determined.

In vitro synergy data (Lipotec, cited in PMC7662462) indicate that combining Snap-8 (0.75 mM) with Leuphasyl/pentapeptide-18 (0.75 mM) produced 47% glutamate-release inhibition versus 43% for Snap-8 alone, suggesting modest additive interaction.

For class-level context, a 2013 randomized, placebo-controlled trial of Argireline (acetyl hexapeptide-3, PMID 23417317) in 60 Chinese subjects reported 48.9% subjective anti-wrinkle efficacy versus 0% placebo (p less than 0.01 for roughness parameters). This applies to the parent hexapeptide, not Snap-8 itself.

Typical dosage: Topical 5-10% (daily).

Snap-8 is available exclusively as a topical cosmetic ingredient and is not used via injection or systemic routes. The commercial ingredient from Lipotec/Lubrizol is supplied as a solution containing 0.05% active peptide in a humectant carrier (glycerin and butylene glycol), intended for incorporation into finished formulations.

• Typical formulation level: 3-10% of the commercial solution in the finished product, equating to approximately 0.0015-0.005% active peptide.

• Application frequency: twice daily, morning and evening, in manufacturer-evaluated protocols.

• Target areas: expression-prone zones including periorbital (crow's feet), glabellar lines, and forehead.

• Duration: the primary manufacturer-reported study used 28-day evaluation; the 2016 JDD open-label study ran 14 weeks. Visible effects, if they occur, are typically assessed at 4-8 weeks of consistent application.

Higher concentrations up to 10% of the commercial solution have appeared in manufacturer documentation. No injectable or intravenous dosing data exist, and Snap-8 has no pharmaceutical drug approval and has not undergone formal dose-ranging clinical trials.

This information is provided for educational and reference purposes only and does not constitute medical advice. Any use of cosmetically active ingredients should be guided by a qualified healthcare or dermatology professional.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The following combinations are primarily drawn from commercial formulations and manufacturer literature rather than independent clinical trials.

• Argireline (acetyl hexapeptide-3/8): The most commonly co-formulated pairing. Both peptides target overlapping N-terminal SNAP-25 regions of the SNARE complex. Manufacturer in vitro data suggest Snap-8 has approximately 30% greater potency than Argireline at equivalent concentrations. No clinical data isolate the incremental benefit of the combination over either peptide alone; evidence for superior outcomes is anecdotal.

• Leuphasyl (pentapeptide-18): Supported by Lipotec in vitro data (cited in peer-reviewed PMC7662462) showing additive inhibition (47% combined vs. 43% for Snap-8 alone and 7% for Leuphasyl alone at 0.75 mM each). This is the best-evidenced combination claim, though it derives from single-laboratory in vitro experiments, not clinical trials.

• Signal peptides such as Matrixyl (palmitoyl pentapeptide-4): Co-formulated in many commercial anti-aging serums to combine neuromuscular inhibition with collagen synthesis stimulation. Clinical evidence for this combination is anecdotal.

• Retinoids and antioxidants: Paired in skincare routines for mechanistically distinct anti-aging effects. No combination studies with Snap-8 have been published; evidence is anecdotal.

Snap-8 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Very safe topically

Snap-8 is classified as a cosmetic ingredient, not a pharmaceutical drug, and is not subject to FDA or EMA drug review. Available safety data derive from manufacturer-sponsored testing and the 2016 JDD open-label study.

In the 2016 JDD study (n=29, 14 weeks of twice-daily topical application of a multi-peptide serum containing acetyl octapeptide-3), no adverse events were reported in any participant.

Systemic absorption is expected to be negligible at cosmetic concentrations. Closely related hexapeptide analogs have been shown in ex vivo studies to penetrate less than 0.2% of the applied dose through the stratum corneum at 24 hours, with 99.7% removed upon washing. While this measurement is for Argireline rather than Snap-8 specifically, the molecular similarity suggests comparably limited percutaneous absorption.

• Known adverse reactions are limited to mild, transient skin irritation or erythema in sensitive individuals. • Allergic contact dermatitis is possible but considered rare. • The ingredient is reported to be non-comedogenic.

No safety data exist for use during pregnancy or breastfeeding, and dermatologists generally advise caution with novel cosmeceutical peptides in these populations. No long-term toxicology studies or drug interaction assessments have been conducted. All available safety evidence comes from cosmetic-context studies and manufacturer data; independent pharmacovigilance for this ingredient does not appear in published peer-reviewed literature.